Galera Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: GRTX · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1563577

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: GRTX

TL;DR

Galera Therapeutics (GRTX) filed an 8-K about a shareholder vote - watch for updates.

AI Summary

Galera Therapeutics, Inc. filed an 8-K on October 18, 2024, reporting on a submission of matters to a vote of security holders. The filing indicates that the company is based in Malvern, PA, and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing signals that Galera Therapeutics is engaging in corporate governance activities requiring shareholder approval, which could impact the company's strategic direction or financial structure.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

FAQ

What specific matters are being submitted to a vote of security holders?

The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 17, 2024.

What is the principal business address of Galera Therapeutics, Inc.?

The principal executive offices are located at 45 Liberty Blvd #230, Malvern, PA 19355.

What is the Standard Industrial Classification code for Galera Therapeutics, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Galera Therapeutics, Inc.?

The SEC file number is 001-39114.

Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-18 08:05:31

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: October 18, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing